Britain and America have established a important trade agreement that will maintain no duties on UK medicine shipments entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to boost funding on pharmaceuticals through the National Health Service (NHS). This move secures that duties on these key products will stay at zero for a period of 36 months.
This development comes after previous threats to hike duties on branded drug products, with increases discussed reaching 100%.
"This agreement with the UK bolsters the international landscape for new treatments and brings long-overdue equity to transatlantic medicine commerce," a release said.
Economic Impact
Drugs represent one of the Britain's most significant exports to the America, which is by far the biggest destination for major British pharmaceutical firms.
Statistics show that in the one-year period to the end of last September, the UK exported medicines worth over eleven billion pounds to the US. This amount made up 17.4% of British export trade in that span.
"This guarantee safeguards employment, boosts funding and facilitates the UK to emerge as a global hub for life sciences," the Business and Trade Secretary remarked.
Key UK Commitments
The agreement entails several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds exceeded twenty percent.
Industry Background
This agreement follows a long-running row between the drug companies and the ministers over drug pricing and approval rates.
This friction were exacerbated by arguments that American consumers were paying significantly more for the identical medicines than consumers in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or scrapped, while major expansions have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had decreased as a proportion of its resources over the last ten years.
